CPAP seems more effective than BiPAP
in ameliorating lung function.
Food and Drug Administration (FDA) granted 510(k) clearance of the BiPAP
autoSV device, which is intended to provide noninvasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA) and Respiratory Insufficiency caused by central and/or mixed apneas and periodic breathing.
In 1992, he presented the Governor's New Product Award to Respironics for its BiPAP
unit, which provides ventilatory assistance to persons who experience difficulty breathing but who are not dependent on a ventilator for life support.
Respironics led the development of the noninvasive bi-level ventilation market with the introduction of its first BiPAP
(R) unit in 1989 and also pioneered the bi-level treatment of Obstructive Sleep Apnea (OSA) through its BiPAP
NASDAQ/NMS:RESP) announced Monday that it has received clearance from the United States Food and Drug Administration to market its BiPAP
S/T-D(R) 30 Ventilatory Support System for use in hospitals and alternate care settings to noninvasively treat appropriate patients suffering from both acute and chronic respiratory insufficiency and respiratory failure.
The need for FDA clearance for these claims for the BiPAP
Ventilatory Support System was one of the items in a December, 1994 warning letter which referenced the system's application in certain critical treatment situations, reported Dennis S.
NASDAQ/NMS:RESP) announced Wednesday that its BiPAP
therapy system has received additional patent protection for its application in the treatment of Obstructive Sleep Apnea (OSA), the world's most prevalent sleep disorder.